Download Image
    
Share
  
Post
Asapiprant for COVID-19
1 study with 194 patients
Hospital Icon Control
Hospital Icon Asapiprant Serious Outcome Risk
No significant improvements are seen in meta analysis to date.
COVID-19 Asapiprant studies. Nov 2025. c19early.org
0 0.5 1 1.5+ All studies -63% Mortality -63% RCTs -63% Late -63% Favorsasapiprant Favorscontrol
Asapiprant (BGE-175) is an oral, small molecule, anti-inflammatory drug that acts as a selective prostaglandin D2 receptor 1 (DP1) antagonist.
May 19
2022
 Wilkerson et al., NCT04705597 A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Investigate the Efficacy and Safety of BGE-175 in Hospitalized Adults With COVID-19
63% higher mortality (p=0.21), 32% higher ICU admission (p=0.37), 24% higher severe cases (p=0.36), and 33% slower improvement (p=0.17). RCT 194 hospitalized COVID-19 patients showing no significant differences with asapiprant (BGE-175).